Literature DB >> 15386350

Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly.

Jerzy E Tyczynski1, Ivan Plesko, Tiiu Aareleid, Maja Primic-Zakelj, Miriam Dalmas, Juozas Kurtinaitis, Aivars Stengrevics, D Maxwell Parkin.   

Abstract

Breast cancer is the cancer diagnosed most frequently in women worldwide. In Europe it is the most common cancer in the female population, with approximately 350,000 new cases diagnosed each year including 130,000 deaths. Incidence rates are increasing in the majority of European countries, whereas a decline in mortality rates has been observed in many West European countries since the late 1980s and early 1990s. Our study examines breast cancer mortality patterns and time trends in the new European Union (EU) member states and compares them with the situation in current EU member states. A Joinpoint regression analysis was used to assess temporal changes in mortality rates and the trends examined in the light of known risk factors, screening programs and advances in treatment. In the majority of the countries analyzed, a deceleration in the increase of mortality rates appeared, followed by a decrease of mortality in many of them in the second half of the 1990s. The declining tendency was visible primarily in young women, and to a lesser extent in middle-aged women, whereas in elderly women a continuing increase of mortality was observed. Analysis of mortality data, information from previous publications, as well as analysis of known factors influencing breast cancer risk suggest that changes observed are due mainly to recent advances in treatment rather than changes in lifestyle risk factors or the result of screening programs. Early detection and a shift toward more favorable stage distribution could have played the leading role for mortality decline in younger patients. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15386350     DOI: 10.1002/ijc.20514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.

Authors:  Stefan Paepke; Volker R Jacobs; Ralf Ohlinger; Mathias Warm; Sherko Kümmel; Anke Thomas; Nadia Harbeck; Marion Kiechle-Bahat
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

2.  Prognostic value of additional pathological variables for long-term survival after curative resection of rectal cancer.

Authors:  Bojan Krebs; Miran Kozelj; Rajko Kavalar; Borut Gajzer; Eldar M Gadzijev
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.

Authors:  Karen Tipples; Anne Robinson
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

4.  A Novel Internet of Things Framework Integrated with Real Time Monitoring for Intelligent Healthcare Environment.

Authors:  A Suresh; R Udendhran; M Balamurgan; R Varatharajan
Journal:  J Med Syst       Date:  2019-05-03       Impact factor: 4.460

5.  Body fluid MMP-2 as a putative biomarker in metastatic breast cancer.

Authors:  Sewon Noh; Jae-Joon Jung; Minkyu Jung; Ki-Hyang Kim; Ha-Young Lee; Brandon Wang; Joanna Cho; Tae Soo Kim; Hei-Cheul Jeung; Sun Young Rha
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

6.  Factors associated with fatigue after surgery in women with early-stage invasive breast cancer.

Authors:  Christine Rotonda; Francis Guillemin; Franck Bonnetain; Michel Velten; Thierry Conroy
Journal:  Oncologist       Date:  2013-02-12

7.  Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes.

Authors:  Elena Afrimzon; Assaf Deutsch; Yana Shafran; Naomi Zurgil; Judith Sandbank; Itzhak Pappo; Mordechai Deutsch
Journal:  Clin Exp Metastasis       Date:  2008-01-16       Impact factor: 5.150

8.  Mortality in 272 European regions, 2002-2004. An update.

Authors:  Luc G Bonneux; Corina C Huisman; Joop A de Beer
Journal:  Eur J Epidemiol       Date:  2009-12-22       Impact factor: 8.082

Review 9.  Continuing with letrozole offers greater benefits.

Authors:  Fritz Jänicke
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-17       Impact factor: 4.322

Review 10.  Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach.

Authors:  Marloes E Clarijs; Jacob Thurell; Friedrich Kühn; Carin A Uyl-de Groot; Elham Hedayati; Maria M Karsten; Agnes Jager; Linetta B Koppert
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.